Study #2024-0424
An open label, multicenter, phase 1 study to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic profile of the PARP1 Inhibitor M9466 alone or in combination in participants with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
M9466, Tuvusertib, Abiraterone acetate, Prednisone/Prednisolone
Description
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-996-1481
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.